CHF 5259

CHF 5259 · Chiesi Farmaceutici S.p.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CHF 5259, covering 2021-06-15 to 2021-06-15. Get the full timeline:

Most recent: Clinical Trial Update: A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease [Phase 2]